Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week

 
• By Michael Cipriano and Brenda Sandburg

The latest drug development news and highlights from our US FDA Performance Tracker. 

Keeping Track Feature image
Viela Bio's inebilizumab for NMOSD and Genfit's elafibranor for PBC win breakthrough designations; Novartis uses priority review voucher for wet AMD treatment brolucizumab.

More from Product Reviews

More from Pink Sheet